Two peptides.
Compelling mechanisms.
What reaches the person?

Semax and Selank have research histories worth examining, but neither a plausible brain mechanism nor an intriguing small study establishes reliable improvements in everyday focus or anxiety. The key distinction is between measured findings and hoped-for benefits. Molecular changes, functional brain images, anxiety scores and recovery after stroke belong to different parts of that story. Moving from one to another requires evidence, not just a persuasive explanation.

Semax is a synthetic peptide related to an adrenocorticotropic hormone fragment. Selank is a different synthetic peptide associated with tuftsin-derived research. Their shared reputation as nootropic peptides can obscure those differences. The Semax literature includes neurotrophin-related animal findings, whereas Selank experiments include changes in genes involved in GABA-related signaling. These are starting points for hypotheses, not interchangeable descriptions of how the two act in people. ^[1][2]

Human reports add more than a purely preclinical story, but they do not remove the uncertainty. Selank has been studied in people with anxiety-related diagnoses. Semax has been examined using functional brain imaging and in stroke rehabilitation. A patient whose anxiety improves, a volunteer whose imaging signal changes and a patient recovering daily activities after a stroke have not demonstrated the same benefit. ^[4][6][7]

For a reader interested in performance, the central question is transfer: does the measured effect occur in the intended population, improve a meaningful outcome and persist under ordinary conditions? A healthy person working through a difficult afternoon is not represented automatically by a clinical anxiety cohort or a rehabilitation ward. This article follows those boundaries while keeping the potential benefits in view. It is a research interpretation, not a recommendation to use either peptide.

The often-repeated BDNF explanation has an identifiable experimental basis. Dolotov and colleagues reported that intranasal Semax affected BDNF and TrkB-related measures in rat hippocampus, alongside a behavioral experiment. The assessed abstract describes changes in protein, messenger RNA and receptor phosphorylation. It does not show that Semax directly binds and activates the BDNF receptor in humans. The full paper was not assessed here, so this article does not reproduce its numerical molecular effects. ^[1]

Those measurements answer different mechanistic questions. Messenger RNA is a step in making a protein; it is not the same thing as the amount of active protein at a synapse. Receptor phosphorylation is a signaling readout, not necessarily evidence that the experimental compound itself occupied that receptor. A behavioral result can strengthen a biological hypothesis without identifying every intervening step. Connecting these measurements is scientifically useful, but collapsing them into 'turns on BDNF' loses information.

A compelling mechanistic account should specify location, timing and consequence. An effect in one brain region at an experimental time point does not establish a desirable, sustained change throughout the brain. Nor does a change in a plasticity-related marker tell us which memories, skills or emotional responses will improve. The question is not whether the marker sounds beneficial. It is whether changing it in this context produces a reproducible outcome that matters to the person.

For everyday focus, the missing bridge is therefore behavioral and clinical. A suitable study would measure a prespecified attention outcome, use an appropriate comparator, control practice effects and report uncertainty around the difference. Measuring a biomarker alongside that outcome could help test the mechanism. Measuring the biomarker alone cannot replace the outcome. This is why the rat work supports further investigation without supplying a reliable expectation of sharper concentration for healthy adults.

A 2016 study examined neurotransmission-related gene expression in male Wistar rat frontal cortex after intranasal Selank, GABA or control treatment. Some patterns suggested GABA-related activity. The experiment did not establish direct receptor action or an anxiety response in humans. ^[2]

The 30 rats supplied tissue pooled into six group-by-time samples. PCR repeats were technical measurements, not additional independent animals. Pooling obscured individual variability. The publisher methods were checked for this distinction; the findings remain hypothesis-generating. ^[2]

Why is the distinction important? A gene can change expression because a cell is responding to a direct receptor effect, compensating for another change, or participating in a broader network response. Similar expression patterns after two interventions do not make those interventions pharmacologically identical. To establish direct receptor action, one would want appropriate binding or functional experiments. To establish clinical benefit, one would additionally want controlled human outcomes.

This is also where comparisons with benzodiazepines can become misleading. A shared connection to inhibitory signaling does not demonstrate an equivalent onset, effect size, withdrawal profile or safety margin. Those are separate empirical questions. Selank's potential appeal is understandable: an intervention that reduced anxiety without impairing performance would be valuable. The research task is to show both sides of that proposition, including objective performance and adverse-event assessment, rather than treating the desired combination as already established.

An intranasal route tells us where a formulation was administered. It does not, by itself, establish how much intact peptide reached a particular part of a human brain, how long it remained there or whether the concentration was sufficient for a proposed action. Delivery, exposure and effect are different questions. A convincing answer needs measurements appropriate to each question, not just the fact that the nose is close to the brain.

A rat study of radiolabeled Semax examined penetration into blood and brain after intranasal administration. Its abstract describes intact peptide alongside degradation products and rapid enzymatic breakdown. The assessed record supports interest in delivery and metabolism, but not a human bioavailability estimate. Radioactivity from a labeled molecule can remain in fragments, so total tracer signal must not automatically be treated as intact, active Semax. ^[3]

These distinctions also limit product-to-study comparisons. A name on a bottle does not establish that its chemical form, concentration, excipients, stability and delivery device match a research preparation. Even a genuine peptide can be delivered under different conditions. An observation with one preparation should not be generalized to every intranasal product, and an intranasal observation should not be carried over to injection or another route without evidence.

For interpreting a future trial, useful details include confirmation of product identity, storage conditions, the administered formulation, exposure measurements where feasible and a clear rationale for timing the outcome tests. A change soon after administration may be interesting, but timing alone does not locate the site of action. Conversely, failure to measure brain exposure does not prove there was none. The honest conclusion is a narrower one: the delivery mechanism and the achieved human exposure remain incompletely characterized in the records reviewed here.

A 2008 report included 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 medazepam. Its English abstract describes anxiety-rating assessments and reports similar anxiolytic effects, alongside other symptom observations. PubMed indexes it as a randomized controlled trial. However, the abstract does not supply enough detail to independently audit masking, allocation methods, treatment exposure or the precision of the group difference. The full Russian-language report was not assessed. ^[4]

A later report compared phenazepam alone in 30 patients with Selank plus phenazepam in 40 patients with anxiety-related disorders. The abstract describes earlier improvement on some assessments and fewer characteristic benzodiazepine adverse effects in the combination group. This is an add-on comparison, not evidence that Selank replaces phenazepam. Detailed methods and numerical between-group effects were unavailable in the assessed abstract. ^[5]

Two common reading errors are especially important here. First, similar reported outcomes do not establish equivalence. An equivalence or noninferiority conclusion needs an appropriate design, a justified margin and confidence intervals that address that margin. Second, improvement during treatment is not necessarily the treatment effect. Symptoms can change with time, expectation, additional care and measurement variability. The comparator and the way participants were allocated determine how much of that change can credibly be attributed to the intervention.

The reports justify interest in anxiety as a research indication, but they do not provide a dependable probability of benefit for a healthy user or a complete safety profile. Readers should also separate relief of anxiety from enhancement of attention. Someone might concentrate better because distress has eased, yet that is different from a direct improvement in attention among people without an anxiety disorder. A future trial could test both, but it should define them as separate outcomes and report each transparently.

A 2018 functional MRI report compared 14 Semax recipients with 10 placebo recipients. Resting-state scans were obtained before and shortly after intranasal administration. The abstract reports a change in the rostral component of the default mode network. This is a functional imaging result. The reported network-volume measure is not evidence that brain tissue grew, and the abstract does not establish improved everyday concentration or memory. ^[6]

A 2020 report examined resting-state functional connectivity in 52 healthy participants receiving Semax, Selank or placebo. It identified between-group and time-related differences, followed by post hoc analysis of connections involving the right amygdala and temporal cortex. This adds human evidence that measured brain-network signals can differ after administration. It does not establish improved focus, reduced clinical anxiety or superiority of either peptide. Administration details were not independently resolved from the abstract. ^[11]

Another 2018 report studied 110 patients at different stages of ischemic-stroke rehabilitation. It examined plasma BDNF and functional measures, including the Barthel index, and reported favorable changes with Semax-containing rehabilitation. The abstract does not provide sufficient allocation detail or numerical treatment-effect information for a strong causal estimate. Plasma BDNF is not a direct measurement of BDNF signaling inside the brain. Findings after stroke also cannot be treated as a healthy-person enhancement trial. ^[7]

The difference is more than a technicality. Resting-state imaging asks how measured signals co-vary while a participant is not performing a specific task. Attention testing asks how accurately or consistently a person performs under defined demands. Daily functioning after stroke asks whether someone can recover activities affected by injury. Each can be valuable, but none is a substitute for the others. Calling them all 'better brain function' makes the evidence sound more unified than it is.

For a persuasive healthy-adult focus claim, the next step would be replicated, adequately powered trials with prespecified tasks, meaningful effect sizes and attention to practice effects. They should distinguish rested participants from sleep-deprived or highly stressed participants, because baseline state may change what improvement means. Benefits should persist beyond a single favorable test or scan. This standard does not dismiss exploratory imaging; it gives imaging its proper role in developing and testing a clinical hypothesis.

The FDA's compounding safety page flags potential immunogenicity, peptide impurities and related characterization concerns for Semax and Selank acetate, alongside limited human safety information for the proposed uses or routes. These statements identify uncertainty and potential hazards. They are not measured rates of harm, and they do not establish that either compound is safe simply because a small study did not reveal a problem. ^[8]

Regulatory context has also changed recently. An October 30, 2026 Federal Register notice describes draft availability and an interim, conditional, nonbinding enforcement-discretion policy for certain 503A peptide compounding. The associated policy includes a formulation- and route-specific Semax free-base intranasal entry. This should not be confused with FDA approval, proof of effectiveness or a blanket endorsement of products sold under the name Semax. The policy's conditions and the scientific evidence are separate issues. ^[9][10]

The practical evidence conclusion is restrained but useful. Semax has animal neurotrophin-related findings and limited human imaging and rehabilitation reports. Selank has GABA-related animal findings and small historical clinical anxiety comparisons. Those signals are reasons to conduct stronger trials. They do not yet justify treating either peptide as a reliably effective focus aid, a proven human BDNF or GABA switch, or an established replacement for an anxiety medicine.

This review used primary PubMed records, accessible publisher full text and official regulatory documents. Several historical clinical reports were available only as English abstracts, and their missing details remain missing here. A ClinicalTrials.gov search did not expose usable results, so this article does not claim that no registered human trials exist. No exhaustive correction or retraction audit was possible. This article was prepared with AI assistance and source checking; it does not represent a clinician's review or individualized treatment advice.